Best Life Sciences Platforms and Tools Companies in Auvergne Rhone Alpes, France
The 56 best Life Sciences Platforms and Tools companies in Auvergne Rhone Alpes, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Mablink.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Auvergne Rhone Alpes
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AD Nucleis Manufacturer of reagents for rapid diagnosis by real-time PCR | — | — | Unfunded | Michel Franck CEO | — | WordPressMySQLPHP+18 | 5 patents Automated data handling for nucleic‑acid extraction robots and real‑time PCR analysis | — |
| 2 | Anaquant Company offering targeted protein (biologics & biomarkers) quantification services by mass spectrometry | — | — | Unfunded | Tanguy Fortin Founder & CEO | 10 | — | 10 patents Patents concentrated in computing, sensing & instrumentation | — |
| 3 | ANS-Biotech Provider of preclinical services on pain models | — | — | Funding Raised | Francois Caussade President & CEO | — | — | — | — |
| 4 | Appolon Bioteck Provider of molecular diagnostic kits for human and animal health, and food security | — | — | Unfunded | SAID EL MOUATASSIM CEO & President | — | — | 2 patents Rapid point‑of‑care nucleic acid amplification and on‑chip detection devices | 2 launchs |
| 5 | BGene Genetics Synthetic biology solutions for industrial biotechnology | — | — | Unfunded | Marie-Gabrielle Jouan CEO | — | — | 21 patents Engineered microbial enzymes for polyketide and phenylpropanoid biosynthesis production | — |
| 6 | BIOTEM Custom Antibodies & Services CRO offering services for the development of custom monoclonal antibodies and immunoassays | — | — | Funding Raised | Clarence Deffaud CEO | — | WordPressMySQLPHP+20 | — | 1 launch |
| 7 | Biovitis Bacterial and fungal biomass production | — | — | Unfunded | Emmanuel Pajot CEO | — | — | 16 patents Patents concentrated in chemistry & materials | — |
| 8 | BlueDNAcompanion Provider of analytical and genomics services | — | — | Deadpooled | Franck Chaubron CEO | — | — | — | — |
Top 12 Life Sciences Platforms and Tools companies in Auvergne Rhone Alpes
#1
Funding Raised · Lyon, Auvergne Rhone Alpes · founded 2009$1.5Mraised▾
CTIBiotech is a developer of 3D human tissue models for the pharmaceutical industry and dermato-cosmetics sectors. The company also claims of printing cancer tissues in 3D using the tools in bioengineering. It offers 3D tissue and cell models to the pharmaceutical industry for cancer research, regenerative medicine, medical devices, public and private research institutions, and organizations. Offers human biological sample procurement & cell harvesting.
- Apr 2026Grant (prize money)$1.5M
#2
Series A · Lyon, Auvergne Rhone Alpes · founded 2018 · 45 employees$8.9Mraised▾
Developer of microfluidic devices for industrial applications. The company has NeoBento a microfluidic platform that focuses on the development of next-generation 3D brain-on-a-chip models for the treatment of neurological diseases.
- Feb 2025Series A$5.1M
- Mar 2022Series A$8.9M
#3
Public · Caluire et Cuire, Auvergne Rhone Alpes · founded 2004 · 37 employees$5.9Mraised▾
3-D Matrix develops synthetic peptides for medical applications. The company synthesizes the self-assembling peptide matrix which is composed of three amino acids in a sequence that is repeated 4 times (Arginine - Alanine - Aspartic Acid - Alanine). The company's product includes PuraStat, a self-assembling synthetic peptide scaffold that mimics the human extra cellular matrix (ECM). The product is used in endoscopic, cardiac, and ENT solutions.
- Nov 2024Post IPO$5.7M
- Jan 2021Grant (prize money)$231.9K
#4
Acquired · Lyon, Auvergne Rhone Alpes · founded 2018 · 29 employees$35Mraised▾
Provider of Antibody-Drug-Conjugates (ADC's) technology for cancer treatment. It offers its propriety hydrophilic linker platform and Mablink’s approach for developing the drug. It forms a non-polymeric of MW 2.0 kD linker which is plasma-stable homogeneous ADCs and doesn't require a site-specific conjugation to binds. The products include MBK-101, MBK-102 for Acute myeloid leukemia, and Multiple myeloma.
- Oct 2022Series A$30.2M
- Apr 2021Seed$4.8M
- 2018Grant (prize money)$1.7M
#5
Public · Lyon, Auvergne Rhone Alpes · founded 1999 · 124 employees$11.6Mraised▾
Genoway develops transgenic rodent models and customized cell lines. It uses homologous recombination, CRISPR/Cas, FLEX, TET, IRES Rosa 26/ Hprt to customize mouse and rat models, cellular models and mouse cell lines with knockout genes and point mutations according to research needs. Therapeutic area applications include neuroscience, immunology, metabolism, cardiovascular disorders, and cancer.
- Jan 2020Grant (prize money)$280.4K
- Feb 2016Grant (prize money)—
- Mar 2014Grant (prize money)$21.4K
- Sep 2004Series B$4.9M
#6
Series C · Grenoble, Auvergne Rhone Alpes · founded 2008 · 36 employees$16Mraised▾
Cytoo specializes in the development of physiologically-relevant cellular models and assays for High Content Screening (HCS). Cytoo’s solutions can transform conventional cellular models grown as heterogeneous monolayers into a more in-vivo like phenotype and morphology through cell micropatterning. The approach can then enable simple conversion of poorly predictable and robust, and low throughput assays, into highly reliable and data rich high content screening efforts. The company develops human striated muscle (MyoScreen) and skin (EpiScreen, FibroScreen) for the pharmaceutical, dermato-cosmetic, nutraceutical, food processing and animal health sectors to screen biologically active compounds. It also develops drugs for treating muscle wasting and Duchenne muscular dystrophy.
- Nov 2011Series C$10M
- Sep 2009Series B$4.7M
- Dec 2008Seed$1.3M
#7
Seed · Saint Martin d Heres, Auvergne Rhone Alpes · founded 2009 · 14 employees$1.1Mraised▾
Smartox is specialized in investigating animal venom properties and manufacturing peptide toxins contained in venoms. It aims to discover innovative drugs from animal venoms. VenomScreen drug discovery services combine a compound library dedicated to HTS programs and hit-to-lead services. It offers a range of animal peptide toxins active on several membrane receptors including ion channels, GPCRs, and integrins. It also offers peptide synthesis service and drug discovery services. Smartox Biotechnology is a spin-off of Grenoble Institute of Neuroscience (partly owned by the University Joseph Fourier, Grenoble, France).
- Oct 2023Grant (prize money)$285.7K
- Mar 2017Seed$992.4K
#8
Seed · Lyon, Auvergne Rhone Alpes · founded 2013 · 7 employees$2.8Mraised▾
Provider of multiplexed assays for determination of the enzymatic status of cellular DNA repair. The platform technology uses a microarray chip that has a series of lesion-containing DNA fragments. Products include Glyco-SPOT kit, a multiplexed fluorescent oligonucleotide cleavage assay that quantifies the activity of eight glycosylases, and AP endonuclease to characterize base excision repair enzymes; and ExSy-SPOT which is a fluorescent assay with plasmid-bearing lesions that quantifies excision/synthesis repair.
- May 2019Grant (prize money)—
- Mar 2019Grant (prize money)$312.6K
- Sep 2017Seed$1.3M
- May 2016Seed$1.5M
#9
Series A · Lyon, Auvergne Rhone Alpes · founded 2011 · 19 employees$2.2Mraised▾
Calixar specializes in the functional and native isolation of complex therapeutic targets & antigens. Its technological platform preserves the original structure of membrane proteins such as GPCRs, Ion channels, Transporters, Viral targets, enzymes and others acting as drug targets or antigens. So pharmaceutical companies, researchers and others can start working with antigens before developing antibodies, formulating vaccines or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays. The company's product pipeline includes candidates for Transporters, Vaccine, GPCR and others.
- Jan 2019Grant (prize money)—
- Feb 2015Series A$1.1M
- Jun 2012Seed$1.1M
#10
Acquired · Ecully, Auvergne Rhone Alpes · founded 2013 · 10 employees$2.4Mraised▾
Mathym is a nanotechnology company dedicated to the development, manufacturing, and commercialization of nanomaterials in the form of colloidal solutions. The company provides its industrial partners with risk-free and fully compatible nano-dispersions that bring or reinforce critical properties within medical devices.
- Oct 2016Series A$2.4M
- Jan 2016Grant (prize money)$292.2K
#11
Funding Raised · Villeurbanne, Auvergne Rhone Alpes · founded 1995 · 27 employees$185.1Kraised▾
Provider of antibody development, engineering, and production services for research. The company offers polyclonal and monoclonal antibody development, DNA immunization, and VHH development. Services also include recombinant protein and antibody production, validation, and engineering. Additional services are peptide synthesis, labeling, purification, fragmentation, and immunogen design support.
- Oct 2023Grant (prize money)$185.1K
#12
Seed · Ruffieux, Auvergne Rhone Alpes · founded 2007$2.4Mraised▾
CellMade Laboratories provides cell biology products and laboratory services. It supports the use of human-origin primary cells as a research tool for in vitro cell-based assays. The company offers cell biology products (human origin cell product) for metabolic disease research, primary cell models (endothelial, epithelial cell), differentiating cell models (adipocytes), advanced cell models, culture media. In addition, they also offer biobank and bioanalysis services.
- Oct 2010Seed$2.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in France
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,937 France-affiliated papers.
- Centre National de la Recherche Scientifique581
- Inserm393
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement130
- Assistance Publique – Hôpitaux de Paris112
- European Molecular Biology Laboratory87
- Genome15→94
- Gene20→91
- Transcriptome2→53
- Chromatin2→28
- Identification (biology)2→27
- Gene4→56
- Transcriptome3→39
- Genome5→24
- Biomarker1→17
- In silico1→16
- Disease3→34
- Gene1→19
- Cancer2→17
- Clinical trial2→16
- Immune system2→14
Where bioinformatics is researched across France
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in France
France bioinformatics patent filing is steady — 2 filings from 4 assignees (2024–2025), led by UNIV Paris CITE, Centre NAT RECH Scient, Ecole NAT Superieure DE Chimie P; annual filings 1→1.
- UNIV Paris CITE2
- Centre NAT RECH Scient2
- Ecole NAT Superieure DE Chimie P1
- Ecole NAT Superieure DE Chimie D1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.